[go: up one dir, main page]

PE20242220A1 - Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer - Google Patents

Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer

Info

Publication number
PE20242220A1
PE20242220A1 PE2024001939A PE2024001939A PE20242220A1 PE 20242220 A1 PE20242220 A1 PE 20242220A1 PE 2024001939 A PE2024001939 A PE 2024001939A PE 2024001939 A PE2024001939 A PE 2024001939A PE 20242220 A1 PE20242220 A1 PE 20242220A1
Authority
PE
Peru
Prior art keywords
cancer
regonafenib
inhibitors
treatment
combination
Prior art date
Application number
PE2024001939A
Other languages
English (en)
Inventor
Sabine Hoff
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20242220A1 publication Critical patent/PE20242220A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a composiciones y combinaciones farmaceuticas que comprenden regorafenib o su hidrato, solvato, metabolito o sal farmaceuticamente aceptable o uno de sus polimorfos y un inhibidor de PD-1/PD-L1(2) para tratar, prevenir o controlar enfermedades o afecciones que incluyen trastornos hiperproliferativos como el cancer en humanos y otros mamiferos. En particular, es una combinacion farmaceutica caracterizada porque comprende regorafenib y pembrolizumab.
PE2024001939A 2017-06-02 2018-05-25 Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer PE20242220A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
PE20242220A1 true PE20242220A1 (es) 2024-11-19

Family

ID=58992733

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002499A PE20200859A1 (es) 2017-06-02 2018-05-25 Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno
PE2024001939A PE20242220A1 (es) 2017-06-02 2018-05-25 Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019002499A PE20200859A1 (es) 2017-06-02 2018-05-25 Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno

Country Status (22)

Country Link
US (4) US11951166B2 (es)
EP (2) EP4342542A3 (es)
JP (3) JP7303122B2 (es)
KR (2) KR102673422B1 (es)
CN (3) CN117582495A (es)
AU (2) AU2018276273B2 (es)
BR (1) BR112019025478A8 (es)
CA (2) CA3244313A1 (es)
DK (1) DK3630112T3 (es)
ES (1) ES2978337T3 (es)
FI (1) FI3630112T3 (es)
HR (1) HRP20240551T1 (es)
HU (1) HUE066487T2 (es)
IL (2) IL317015A (es)
LT (1) LT3630112T (es)
MX (1) MX2023001721A (es)
PE (2) PE20200859A1 (es)
PL (1) PL3630112T3 (es)
PT (1) PT3630112T (es)
RS (1) RS65488B9 (es)
SI (1) SI3630112T1 (es)
WO (1) WO2018219807A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066487T2 (hu) * 2017-06-02 2024-08-28 Bayer Healthcare Llc Regorafenib és nivolumab kombinációja rák kezelésére
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
RS57875B1 (sr) 2012-09-25 2018-12-31 Bayer Pharma AG Kombinacija regorafeniba i acetilsalicilne kiseline za lečenje kolorektalnog kancera
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
EP3498734B1 (en) 2014-02-04 2021-09-01 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US20170165364A1 (en) 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
CA2954508A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN107072984B (zh) 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
EP3463456A1 (en) 2016-06-03 2019-04-10 ImClone LLC Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
HUE066487T2 (hu) * 2017-06-02 2024-08-28 Bayer Healthcare Llc Regorafenib és nivolumab kombinációja rák kezelésére
KR102692379B1 (ko) * 2017-06-05 2024-08-05 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 사용 방법

Also Published As

Publication number Publication date
CN117899212A (zh) 2024-04-19
HUE066487T2 (hu) 2024-08-28
US11517622B2 (en) 2022-12-06
DK3630112T3 (da) 2024-04-22
KR102673422B1 (ko) 2024-06-07
US20200155674A1 (en) 2020-05-21
FI3630112T3 (fi) 2024-05-02
RU2019143599A3 (es) 2021-09-10
CN110662540B (zh) 2024-01-26
CA3244313A1 (en) 2025-06-13
BR112019025478A2 (pt) 2020-06-23
US11951166B2 (en) 2024-04-09
EP4342542A2 (en) 2024-03-27
IL317015A (en) 2025-01-01
IL270948B1 (en) 2025-03-01
CA3065125C (en) 2025-06-10
US20200188372A1 (en) 2020-06-18
EP3630112A1 (en) 2020-04-08
MX2023001721A (es) 2023-02-22
SI3630112T1 (sl) 2024-06-28
US20220133888A1 (en) 2022-05-05
EP3630112B1 (en) 2024-01-31
IL270948A (en) 2020-01-30
IL270948B2 (en) 2025-07-01
RU2019143599A (ru) 2021-07-09
KR20200011971A (ko) 2020-02-04
CN117582495A (zh) 2024-02-23
AU2023282197B2 (en) 2025-06-26
ES2978337T3 (es) 2024-09-10
JP7303122B2 (ja) 2023-07-04
AU2018276273B2 (en) 2023-12-21
JP2020521786A (ja) 2020-07-27
KR20240091188A (ko) 2024-06-21
PL3630112T3 (pl) 2024-07-01
AU2023282197A1 (en) 2024-01-04
US20200179354A1 (en) 2020-06-11
PT3630112T (pt) 2024-04-23
EP4342542A3 (en) 2024-06-05
CN110662540A (zh) 2020-01-07
RS65488B1 (sr) 2024-05-31
KR102843438B1 (ko) 2025-08-06
LT3630112T (lt) 2024-05-10
BR112019025478A8 (pt) 2022-12-06
JP7475402B2 (ja) 2024-04-26
EP3630112B9 (en) 2024-06-26
PE20200859A1 (es) 2020-08-25
JP2022169780A (ja) 2022-11-09
HRP20240551T1 (hr) 2024-07-05
RS65488B9 (sr) 2024-09-30
JP2024096905A (ja) 2024-07-17
AU2018276273A1 (en) 2019-12-12
WO2018219807A1 (en) 2018-12-06
CA3065125A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
NZ770260A (en) Substituted heterocyclic inhibitors of ptpn11
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX393976B (es) Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.
CR20190394A (es) Compuestos de inhibidores de autotaxina
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MX381342B (es) Compuestos terapeuticos inhibidores.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
JOP20190262B1 (ar) مثبطات بيرازول magl
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX394452B (es) Inhibicion de la actividad de olig2.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
PE20242220A1 (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer
BR112022003768A2 (pt) Compostos inibidores de perk